Abstract 1359
Background
Across the most commonly diagnosed cancers (breast, colorectal, lung and prostate), advances in curative treatment have led to improvements in cancer survival. Workplace policies for medical leave however, may have been instituted when surgery alone was sufficient treatment for cancer. The duration of adjuvant therapy may not be incorporated into laws providing temporary financial assistance or protecting patients from workplace dismissal. Our objective is to determine the median duration of curative treatment and recovery time for the four common cancers and to understand the implications in the broader context.
Methods
BC Cancer provides cancer care for a population of 4.6 million. A retrospective review was completed of referred patients from 2010-2016, ≤ 65 years old, newly diagnosed with stage I-III breast, colorectal, lung, prostate cancer, received curative intent treatment that includes either chemotherapy or radiotherapy. Information was collected on baseline characteristics, date of diagnosis, surgical procedure and date, radiotherapy type, duration and intent (neoadjuvant/ concurrent/ adjuvant), chemotherapy type, duration and intent.
Results
26,995 patients were included in the study, 11,911 (44%) received definitive radiotherapy or multimodality treatment.Table: 1655P
Breast N = 12706 | Prostate N = 6360 | Colorectal N = 5336 | Lung N = 2593 | |
---|---|---|---|---|
No adjuvant treatment | 4605 | 5377 | 3491 | 1611 |
Definitive radiation or multimodality treatment | 8101 | 983 | 1845 | 982 |
Median time from diagnosis to definitive treatment (weeks) | 5.14 | 13.71 | 4.29 | 5.42 |
Median time between definitive treatment and adjuvant therapy (weeks) | 8.14 | 18.14 | 8.42 | 8.57 |
Median duration of adjuvant chemotherapy (weeks) | 14.29 | N/A | 20.00 | 10.00 |
Median duration of adjuvant radiation +/- chemotherapy (weeks) | 3.85 | 6.71 | 5.00 | 5.57 |
Median duration of definitive radiation +/- chemotherapy (weeks) | N/A | 6.42 | N/A | 6.42 |
Median duration from definitive treatment to completion of all treatment (weeks) | 23.57 | 6.85 | 28.29 | 18.00/6.14* *chemo/xrt |
Conclusions
Almost half of patients who undergo curative cancer treatment require definitive radiotherapy or multimodality treatment. The median duration of therapy varies widely depending on primary site and modality (6.14 - 28.29 weeks). This has implications for financial support such as United Kingdom’s Statutory Sick Pay (28 weeks) and Canada Employment Insurance (15 weeks), as well as workplace dismissal in the United States where the Family and Medical Leave Act protects employees for 12 weeks absence. Governments should consider amending the laws to reflect current cancer treatment durations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Ho: Honoraria (self), Research grant / Funding (self): AstraZeneca; Honoraria (self), Research grant / Funding (self), Travel / Accommodation / Expenses: Boehringer Ingelheim; Honoraria (self), Travel / Accommodation / Expenses: Pfizer ; Honoraria (self): BMS; Honoraria (self), Travel / Accommodation / Expenses: Roche; Honoraria (self): Lilly; Research grant / Funding (self): Genzyme; Honoraria (self), Research grant / Funding (self): Eisai; Honoraria (self): Merck; Honoraria (self): Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
2494 - CAR-T Nursing Education at a UK Specialist Cancer Hospital
Presenter: Rose Ellard
Session: Poster Display session 3
Resources:
Abstract
2438 - Professional Quality of Life, Perceived Stress and Psychological Resistance Levels of Oncology-Hematology Nurses and the Factors Affecting
Presenter: Tugba Pehlivan
Session: Poster Display session 3
Resources:
Abstract
3541 - Representation of cancer survivors’ preferences in policies for supportive care: Implications for oncology nursing
Presenter: Samantha Mayo
Session: Poster Display session 3
Resources:
Abstract
5093 - Vaginal moisturizing post PDR-Pulse Dose Rate Brachytherapy.
Presenter: Pilar Fernández
Session: Poster Display session 3
Resources:
Abstract
1066 - The stomized, chemo and radiotreated patient vs untreated patient: complications and comparison with data literature
Presenter: Cristoforo Ferrero
Session: Poster Display session 3
Resources:
Abstract
1724 - Evaluating the role of clinical nurse specialist
Presenter: Anita Zeneli
Session: Poster Display session 3
Resources:
Abstract
3753 - Role of the Advanced Practice Nurse (APN) in a Functional Unit for Lung cancer at the Catalan Institute of Oncology
Presenter: Isabel Brao
Session: Poster Display session 3
Resources:
Abstract
2676 - A bottom-up approach for prioritising the scientific activities of the Italian Association of Cancer Nurses (AIIAO): rationale and topic identification
Presenter: Valentina Biagioli
Session: Poster Display session 3
Resources:
Abstract
575 - Investigating quality of care for people with cancer and dementia
Presenter: Naomi Farrington
Session: Poster Display session 3
Resources:
Abstract
5578 - Two years of BRCA1 and BRCA2 somatic External Quality Assessment with Gen&tiss Tiss scheme in France
Presenter: Kelly Dufraing
Session: Poster Display session 3
Resources:
Abstract